These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16820335)

  • 1. Clinical treatment outcomes of periodontal therapy in HIV-seropositive patients undergoing highly active antiretroviral therapy.
    Jordan RA; Gängler P; Jöhren HP
    Eur J Med Res; 2006 Jun; 11(6):232-5. PubMed ID: 16820335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodontal conditions and distribution of Prevotella intermedia, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans in HIV-infected patients undergoing anti-retroviral therapy and in an HIV-seronegative group of the Venezuelan population.
    Brito A; Escalona LA; Correnti M; Perrone M; Bravo IM; Tovar V
    Acta Odontol Latinoam; 2008; 21(1):89-96. PubMed ID: 18841752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence.
    Gaitan Cepeda LA; Ceballos Salobreña A; López Ortega K; Arzate Mora N; Jiménez Soriano Y
    Med Oral Patol Oral Cir Bucal; 2008 Feb; 13(2):E85-93. PubMed ID: 18223535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
    Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of patient-centered plaque control and periodontal maintenance therapy on adverse outcomes of periodontitis.
    Pastagia J; Nicoara P; Robertson PB
    J Evid Based Dent Pract; 2006 Mar; 6(1):25-32. PubMed ID: 17138393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes of repeated adjunctive photodynamic therapy during periodontal maintenance: a proof-of-principle randomized-controlled clinical trial.
    Lulic M; Leiggener Görög I; Salvi GE; Ramseier CA; Mattheos N; Lang NP
    J Clin Periodontol; 2009 Aug; 36(8):661-6. PubMed ID: 19563331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
    Lindsey JC; Malee KM; Brouwers P; Hughes MD;
    Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Highly active antiretroviral therapy in HIV sero-positive children. Disease progression by baseline clinical, immunological and virological status].
    Rodríguez de Schiavi MS; Scrigni A; García Arrigoni P; Bologna R; Barboni G; Redondo J; Nastri M; Mecikovsky D; Cantisano C; Moreno R; Siciliani D; Lencina M; Luedicke N; Rezzónico G; Torolla JL; López Papucci S; Luis M; Libonati C; Gamba L; Barbarysky J; Pérez Hernández E; Zlatkes R
    Arch Argent Pediatr; 2009 Jun; 107(3):212-20. PubMed ID: 19543629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necrotizing periodontal diseases in HIV-seropositive subjects: pathogenic mechanisms.
    Feller L; Lemmer J
    J Int Acad Periodontol; 2008 Jan; 10(1):10-5. PubMed ID: 18333595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients.
    Alciati A; Gallo L; Monforte AD; Brambilla F; Mellado C
    Hum Psychopharmacol; 2007 Jan; 22(1):33-40. PubMed ID: 17191264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodontal healing after non-surgical therapy with a modified sonic scaler: a controlled clinical trial.
    Christgau M; Männer T; Beuer S; Hiller KA; Schmalz G
    J Clin Periodontol; 2006 Oct; 33(10):749-58. PubMed ID: 16889629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implant-prosthetic treatment in HIV-infected patients receiving highly active antiretroviral therapy: report of cases.
    Strietzel FP; Rothe S; Reichart PA; Schmidt-Westhausen AM
    Int J Oral Maxillofac Implants; 2006; 21(6):951-6. PubMed ID: 17190306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of supportive periodontal therapy (SPT) in HIV-seropositive and HIV-seronegative patients.
    Hofer D; Hämmerle CH; Grassi M; Lang NP
    J Clin Periodontol; 2002 Jul; 29(7):630-7. PubMed ID: 12354088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
    Fardet L; Mary-Krause M; Heard I; Partisani M; Costagliola D;
    HIV Med; 2006 Nov; 7(8):520-9. PubMed ID: 17105511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.